NBE Therapeutics, founded in 2012 and acquired by Boehringer Ingelheim in 2020, headquartered in Basel, Switzerland, is a renowned biotechnology company at the forefront of developing next-generation ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company's aim of transforming the lives of people with cancer.

CHF 27 million investment significantly bolsters Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.

Aligos Therapeutics has a one year low of $6.76 and a one year high of $46.80. The stock has a market capitalization of $43.65 million, a price-to-earnings ratio of -0.54 and a beta of 2.52.

The latest price target for Aligos Therapeutics (NASDAQ:ALGS) was reported by HC Wainwright & Co. on March 31, 2025. The analyst firm set a price target for $70.00 expecting ALGS to rise to within ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Utilising Alnylam Pharmaceuticals’ ESC-GalNAc conjugate technology, Qfitlia prevents bleeds and helps rebalance haemostasis by lowering antithrombin, a protein that inhibits blood clotting. The ...